Marjorie C. Green

发表

TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

R. Bourgon, P. Hegde, Yulei N. Wang, 2018, Nature.

Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Christos Hatzis, Lajos Pusztai, Henry Kuerer, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.

K. Hess, G. Hortobagyi, L. Pusztai, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

P. Hegde, A. Ravaud, T. Powles, 2018, The Lancet.

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.

Roman Rouzier, Lajos Pusztai, Kenneth R Hess, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response

Roman Rouzier, Lajos Pusztai, Terry L. Smith, 2004, Cancer.

Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.

P. Hegde, R. Motzer, T. Powles, 2020, Cancer cell.

Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer.

G. Hortobagyi, K. Hunt, V. Valero, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women.

V. Valero, R. Theriault, R. Carlson, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Short-Term Biomarker Modulation Prevention Study of Anastrozole in Women at Increased Risk for Second Primary Breast Cancer

Diane D. Liu, G. Hortobagyi, N. Sneige, 2011, Cancer Prevention Research.

Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.

J. Baselga, K. Blackwell, S. Verma, 2017, The Lancet. Oncology.

Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome.

H. Kuerer, K. Hunt, S. Curley, 2012, Surgery.

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.

Yuan Qi, Christos Hatzis, Lajos Pusztai, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy

W. Woodward, G. Babiera, T. Buchholz, 2013, Radiation Oncology.

Fast dixon‐based multisequence and multiplanar MRI for whole‐body detection of cancer metastases

Jingfei Ma, Fei Sun, Vikas Kundra, 2009, Journal of magnetic resonance imaging : JMRI.

Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases

G. Hortobagyi, V. Valero, D. Booser, 2014, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.

G. Hortobagyi, T. Buchholz, W. Yang, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma

J. Stec, M. Ayers, K. Hess, 2003, Cancer.

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.

Terry L. Smith, D. Berry, G. Hortobagyi, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study.

P. Hegde, A. Ravaud, T. Powles, 2018 .

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

C. Porta, A. Ravaud, R. Motzer, 2019, The Lancet.

Chemotherapy for Breast Cancer

G. Hortobagyi, Marjorie C. Green, 2008 .

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks.

Terry L. Smith, G. Hortobagyi, L. Pusztai, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor–positive metastatic breast cancer

G. Hortobagyi, J. Murray, F. Esteva, 2012, Cancer Chemotherapy and Pharmacology.

HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer

G. Hortobagyi, L. Pusztai, W. Symmans, 2008, Breast Cancer Research and Treatment.

Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population

S. Gomez, A. Kurian, Marjorie C. Green, 2016, Cancer Causes & Control.

Medical Therapy of Locally Advanced Breast Cancer

G. Hortobagyi, S. Giordano, Marjorie C. Green, 2006 .

Neoadjuvant chemotherapy for operable breast cancer.

G. Hortobagyi, Marjorie C. Green, 2002, Oncology.

Radiation dose escalation for loco-regional recurrence of breast cancer after mastectomy

W. Woodward, G. Babiera, T. Buchholz, 2013, Radiation oncology.

Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population

S. Gomez, A. Kurian, Marjorie C. Green, 2016, Cancer Causes & Control.

Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting.

K. Hess, G. Hortobagyi, V. Valero, 2012 .

Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy

S. Singletary, H. Kuerer, K. Hunt, 2006, Annals of Surgical Oncology.

Adjuvant chemotherapy for breast cancer

G. Hortobagyi, Marjorie C. Green, 2002, Langenbeck's Archives of Surgery.

Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC).

R. Motzer, T. Powles, M. Atkins, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of Ductal Lavage and Random Periareolar Fine Needle Aspiration as Tissue Acquisition Methods in Early Breast Cancer Prevention Trials

Kristine Broglio, Henry Kuerer, G. Hortobagyi, 2007, Clinical Cancer Research.

Diseases of the Breast

K. Hunt, T. Buchholz, Marjorie C. Green, 2012 .

Contrast-Enhanced Computed Tomography Evaluation of Hepatic Metastases in Breast Cancer Patients before and after Cytotoxic Chemotherapy or Targeted Therapy

R. Theriault, C. Charnsangavej, W. Yang, 2015, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

K. Hess, G. Hortobagyi, L. Pusztai, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations

G. Hortobagyi, V. Valero, N. Ibrahim, 2013, Clinical & Experimental Metastasis.

Diseases of the Breast

K. Hunt, T. Buchholz, Marjorie C. Green, 2012 .

Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations

G. Hortobagyi, V. Valero, N. Ibrahim, 2013, Clinical & Experimental Metastasis.

Survival among women with triple receptor-negative breast cancer and brain metastases.

F. Esteva, A. González-Angulo, Marjorie C. Green, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.

G. Hortobagyi, L. Pusztai, H. Kuerer, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations.

G. Hortobagyi, L. Pusztai, V. Valero, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.